Sohm Inc - SHMN STOCK NEWS

SOHM, Inc. appoints Wm. Dewey Rushing as Vice President-Quality, bringing valuable expertise in pharmaceutical quality validation and compliance. Rushing's experience will be valuable as the company diversifies its portfolio and expands to new markets.

SOHM, Inc. appoints Dr. Krishna Bhat as Chief Medical Advisor, bringing valuable expertise in cardiology. Dr. Bhat's experience will support the planned acquisition of ABBIE Technology and its innovative patents, clinical trials, diagnostic kits, and cardiac treatments. Dr. Bhat is a renowned Clinical and Interventional Cardiologist with over 35 years of practice and has authored 16 medical scientific publications. The acquisition of ABBIE Technology and the development of the San Diego plant are expected to create new opportunities and increase revenues for SOHM.

SOHM, Inc. has signed a letter of intent to acquire stem cell disruptive technology and patents called 'ABBIE'. The technology aims to create novel products and solutions in the regenerative medicine and cosmeceutical industries. The patents have been approved in China and are pending in the U.S., EU, Japan, and South Korea.

SOHM Inc. has secured $5 million in financing for its San Diego pharmaceutical plant and future projects. The funding will support the company's growth strategy and allow for faster plant operations.

SOHM, Inc. (OTC PINK: SHMN) announced an exclusive distribution agreement with Stallion Laboratories Pvt. Ltd. to launch Levetiracetam, a medication for treating epilepsy. Levetiracetam, an FDA-approved anticonvulsant, will be manufactured in Ahmedabad, India, and distributed under SOHM's label. The product is anticipated to generate annual revenues between US$3-5 million, aiming for a 5-10% market share over the coming months. The global antiepileptic drug market is projected to grow at a CAGR of 3.9% from 2021 to 2031, driven by rising epilepsy prevalence. The launch is expected within two months, offering a new treatment option that is particularly beneficial for older adults with dementia.

SOHM, Inc. (OTC PINK:SHMN) announced the launch of its new Topical Skincare line, which includes nine products aimed at treating various dermatological conditions. The company has received orders for two products and five SKUs, with distribution set for retail chains such as Walmart and Publix by late May 2023. CEO Baron Night highlighted the potential for significant revenue growth in the skincare market, projected to reach multi-million dollar sales annually. SOHM also reintroduced an OTC product—a Unisex foam formulation featuring Salicylic Acid for acne and anti-aging. The company aims for organic revenue growth alongside new product pipelines.

SOHM, Inc. (OTC PINK:SHMN) has signed a memorandum of understanding with SRAM & MRAM Group for funding its new pipeline projects. This partnership aims to support the company’s growth initiatives that include manufacturing facilities, a potential acquisition, and new product development aligned with its vision of Globalé Prospéro. The funding is expected to be significant and non-toxic, with SRAM & MRAM having a strong record in project financing, including a $900 million infusion. SOHM anticipates completing its projects swiftly, contingent on government approvals.

SOHM, Inc. (SHMN) has appointed Dr. David Aguilar to its Advisory Board as an Expert Medical Advisor. Dr. Aguilar brings extensive expertise in CMC activities for allogeneic cell-based therapies, pharmacology, genome editing, and regenerative medicine. His track record includes co-founding Exeligen Scientific Inc. and establishing regenerative medicine-focused facilities across North America. President and CEO Baron Night expressed confidence that Dr. Aguilar's experience will enhance SOHM's current and future product pipelines. Further appointments are expected soon.